Mutaflor and Mutaflor Suspension
The broad application range of the unique probiotic API E. coli strain Nissle 1917
Current registrations, clinical studies and casuistics demonstrate the broad range of Mutaflor applications. This reaches from chronic bowel diseases to the colonization prophylaxis of premature and full-term neonates all the way to the treatment of extraintestinal diseases.
The limitations of antibiotic therapy, which are becoming more and more visible by the development of multiresistant pathogenic microorganisms, heighten the interest in the probiotic medicinal product Mutaflor, containing E. coli strain Nissle 1917 as the active substance. New knowledge about the medicinal relevance of the microbiome to human health have been added.
On the following sites, we present an overview on the latest non-medical (pre-clinical) findings concerning the unique properties of E. coli strain Nissle 1917, as well as on the clinical experiences that have been made with Mutaflor treatment of patients.
Comprehensive fulfillment of all microbiological and molecular biological safety requirements
Efficacy
- Efficacy in defined indications evidenced by controlled clinical studies
Mechanism of action
- Suppression of growth and colonization of undesired microorganisms
- Contribution to optimizing the intestinal milieu and luminal metabolism
- Communication with the intestinal epithelium
- Colonization ability
Product quality
- Microbiological purity
- Defined number of viable cells
- Exact identification and differentiation from closely related microorganisms
- Viability in the gastrointestinal tract
Safety
- Non-pathogenicity
- Genetic stability